Wuhan Desheng Biochemical Technology Co., Ltd

Phosphate cellulose column chromatography, as one of the core technologies in the field of biological molecule separation and purification, plays an important role in the preparation of biomolecules such as proteins and nucleic acids due to its efficient adsorption and separation performance. The core principle of this technology is to utilize the specific binding between the phosphate groups on the surface of phosphate cellulose medium and biomolecules, such as electrostatic interactions and hydrogen bonding, to achieve precise separation of target molecules. In this process, the selection and optimization of buffer directly affect the chromatography effect, and MES buffer, due to its unique physicochemical properties, has become the ideal choice for balancing and elution steps in this technology. The primary application of MES buffer (2-morpholine ethanesulfonic acid buffer) in phosphocellulose column chromatography is as an equilibrium solution, providing a stable initial environment for the chromatography system. Before starting the chromatography operation, a large amount of equilibrium solution needs to flow through the chromatography column to achieve thermodynamic equilibrium between the stationary phase (cellulose phosphate medium) and the mobile phase (MES buffer). The phosphate groups on the surface of the phosphate cellulose medium will dissociate under specific pH conditions, and the pH buffering range of MES buffer solution precisely matches the optimal working pH range of phosphate cellulose, which can accurately maintain the stability of the surface charge state of the medium. This stability ensures that the column is in a uniform initial state before sample loading, effectively avoiding differences in adsorption efficiency caused by local pH fluctuations, and laying the foundation for the repeatability and stability of subsequent separation. At the same time, the extremely low UV absorption characteristics of MES buffer also reduce interference with target molecule detection. During the elution stage, MES buffer achieves gradient separation of biomolecules by precisely regulating ion strength and pH value. The binding strength between biomolecules and phosphate cellulose medium depends on the electrostatic attraction between the surface charge of the molecule and the phosphate groups in the medium, which can be adjusted by changing the ionic strength of the buffer solution. In experiments, a mixed system of MES buffer and sodium chloride is usually used. By gradually increasing the concentration of sodium chloride (i.e. increasing the ionic strength), the ions in the solution compete with biomolecules to bind to the charged sites on the surface of phosphocellulose, thereby weakening the interaction between biomolecules and the medium. Due to the differences in the charged properties and molecular weight of different biomolecules, their binding strength with the medium varies. Therefore, they will be eluted successively in MES buffer solutions with different ionic strengths to achieve separation and purification. In addition, MES buffer has high chemical stability and is not easily reacted with biomolecules during chromatography, which can effectively maintain the natural structure and activity of biomolecules. This is crucial for subsequent functional research or applications. Meanwhile, its good solubility and low osmotic pressure also reduce damage to the chromatography column and potential impact on biomolecules. In summary, MES buffer plays an irreplaceable key role in phosphocellulose column chromatography technology by serving as an equilibrium solution to ensure the initial stability of the chromatography system and as an eluent to achieve precise separation of biomolecules through ion strength regulation. It provides an efficient and reliable solution for the separation and purification of biomolecules. As an advantageous manufacturer of MES buffer, Desheng, with its professional R&D team, advanced production technology, and strict quality control system, can stably supply high-quality MES buffer products with high purity, good stability, and excellent biocompatibility, which can meet the needs of biochemical experiments in different fields. If you have any relevant intentions, please click on the website to inquire about details and purchase!  

In the golden September, Yangcheng gathers. From September 26th to 29th, 2025, the global healthcare industry will once again focus on Guangzhou, welcoming the grand opening of the 92nd China International Medical Equipment Fair (CMEF). As an innovative force in the field of core raw materials for in vitro diagnostics (IVD), Hubei Xindesheng Materials Technology Co., Ltd. is ready to go. Led by the company's general manager, an elite team consisting of technical elites and domestic and foreign sales backbones set off from Hubei on September 25th to attend this top-level industry event (booth number: C06 in Hall 20.1), aiming to present a precise diagnostic technology feast to global customers with a series of innovative enzyme preparations and mature core products. 1, Innovation engine: New enzyme preparations make a heavyweight debut, empowering precise diagnosis in new dimensions At this year's CMEF, Xindesheng will launch a new generation of high-purity and highly stable enzyme preparation series that it has carefully developed, including key indicator detection materials such as lactate dehydrogenase (LDH), uricase (UO), creatine kinase isoenzyme (CK-MB), etc. These new products are not only a concentrated reflection of the company's research and development capabilities, but also directly address the higher demand for detection sensitivity, specificity, and inter batch stability in the current IVD testing market. These new enzyme preparations have injected strong power into Xindesheng's "innovation engine", indicating that the company has taken a more solid step on the road of independent research and development of key raw materials, aiming to help downstream reagent manufacturers enhance their product core competitiveness. 2, Stable cornerstone: Core product matrix appears together, showcasing the full chain supply strength While showcasing its innovative edge, Xindesheng will also showcase its traditional core product matrix that has been validated in the market for a long time, demonstrating its comprehensive strength as a reliable supplier. Biological buffering agents, such as Tris, HEPES, Bicine, etc., have excellent purity and provide a stable reaction environment for diagnostic reagents. Chemiluminescent reagents, including luminol and acridine ester luminescent reagents, have the advantages of high luminescence efficiency and sensitive reaction. Chromogenic substrates such as TOOS, TOPS, MAOS, MADB, etc. are sensitive and stable for color development, and are suitable for various enzyme immunoassay analyses. Blood collection tube additives: a full range of products including serum separation gel, anticoagulant, coagulant, silicification agent, etc., provide support for front-end sample processing. New Desheng's product line covers multiple key aspects of IVD reagent development and production, including reaction environment construction, signal generation, and sample preprocessing, demonstrating its strong ability to provide customers with a "one-stop" raw material solution. 3, Face to face communication: Elite teams gather to discuss new chapters of cooperation In this exhibition, Xindesheng not only sent out products, but also a powerful "think tank" and "service team". The general manager, technical experts, and domestic and foreign sales elites gather together to have zero distance and in-depth communication with customers and partners from around the world. Whether it's exploring cutting-edge technology trends, analyzing specific project requirements, or negotiating customized services and international market cooperation, the New Desheng team is fully prepared and looks forward to colliding ideas and listening to market voices on the open platform of CMEF. With more flexible and thoughtful services, we will explore the infinite possibilities of diagnostic technology development together with industry colleagues. Conclusion: At the right time for the grand event, Xindesheng is waiting for your visit in Guangzhou! The exhibition has now grandly opened, and excitement is unfolding! The booth of Hubei Xindesheng is ready, and our team is eagerly awaiting the visit of all new and old friends in Guangzhou with full enthusiasm. Now, by visiting the New Desheng booth (booth number: C06, Hall 20.1), you will be able to: Personally observe and understand the appearance and excellent performance of new enzyme preparations and core products; Face to face with the general manager and technical experts to deeply discuss your customized needs and technical challenges; Obtain the latest product information and cooperation policies. The opportunity is rare, and the grand event is in full swing! We look forward to meeting you in Yangcheng, seeking common development and a win-win future!

On September 19, 2025, the golden autumn brings a refreshing feeling and the fragrance of osmanthus flowers fills the air. In this beautiful season of harvest and hope, we warmly welcome our important strategic partner from afar - Ms. Anu Moturi, founder of Kriya Medical Technologies (KriyaMed), an Indian blood collection industry enterprise. This visit is a deep interaction between the two sides after embarking on a journey of cooperation, aimed at reviewing the fruitful cooperation process and jointly drawing up a grand blueprint for future development. During the visit, both parties held talks on the in-depth cooperation and future market strategy of EDTA K3 and separation gel, and conducted on-site inspections of our new Huanggang factory. Both sides walked together, sharing their cooperative friendship and seeking common development plans, creating a warm and harmonious atmosphere on site. Under the leadership of founder Anu Moturi, KriyaMed has become an undeniable force in the Indian blood collection tube market. Since establishing a partnership with our company 6-7 years ago, both parties have supported each other and grown together. Ms. Anu Moturi's personal visit this time not only reflects her appreciation for the long-term cooperative relationship with our company, but also demonstrates her firm determination to further deepen cooperation and jointly explore the market. At the beginning of the visit, our company's Chairman Mr. Wang Zhongxi, General Manager Ms. Wang Anqi and other senior leaders expressed their warmest welcome to Ms. Anu Moturi's visit. During the cordial and friendly talks, both sides jointly reviewed the achievements of their cooperation over the past five years. Ms. Anu Moturi expressed her sincere gratitude to our company for providing stable and high-quality product supply, as well as timely and professional technical services. She clearly stated that one of the core objectives of this visit is to explore with our company a more competitive cooperation price for EDTA K3 anticoagulant and core raw material separation gel based on a larger procurement scale in the future, in order to further enhance the competitiveness of KriyaMed products in the Indian market. More notably, Ms. Anu Moturi confidently shared KriyaMed's next strategic development plan. She announced that the company has set clear goals to significantly increase the production capacity and market share of separation gel blood collection tubes, striving to become the leader in the Indian separation gel blood collection tube market. To achieve this ambitious goal, KriyaMed plans to increase its procurement of separation gel from our company on one hand, and on the other hand, invest heavily to enhance its own production capacity. She emphasized that establishing a deeper strategic alliance with our company, a source enterprise with strong technology and production capacity guarantee, is the core cornerstone to achieve this goal. In order to enable our esteemed partners to fully understand our strength and commitment, Mr. Wang Zhongxi, Chairman, and Ms. Wang Anqi, General Manager, personally accompanied Ms. Anu Moturi to visit and inspect our new factory located in Huanggang. On this trip, she not only saw the strong existing production capacity of your company, but also saw the huge development potential for the future. She highly appreciates our company's continuous investment in production capacity and technological upgrades, believing that this provides a solid and reliable guarantee for its future large-scale procurement needs, and is full of confidence in the stability and growth of our long-term cooperation. The successful visit of Ms. Anu Moturi marks a new and deeper stage in our partnership with KriyaMed after five years of testing. From stable suppliers to strategic partners working together, this transformation is based on deep mutual trust and a shared vision. We firmly believe that with Ms. Anu Moturi's outstanding leadership and clear market strategy, the strong alliance between the two parties will bear even more fruitful results. Hubei Xindesheng will spare no effort to support Kriya Medical Technologies in achieving its grand goal of becoming a market leader in India with competitive prices, stable product quality, and a reliable supply chain, and jointly create a mutually beneficial and win-win future!

In life science research, the pH stability of the experimental environment is a core factor affecting cell activity, enzyme catalytic efficiency, and protein structural integrity. As a classic buffer in the neutral to weakly alkaline range, 3- (N-morpholino) propanesulfonic acid (MOPS buffer) is widely used in fields such as cell culture, protein purification, and nucleic acid electrophoresis due to its excellent buffering capacity and biocompatibility. However, the concentration control of MOPS directly determines its buffering efficiency, and improper concentration may cause experimental deviation or even failure. 1, Dynamic balance between concentration and buffering capacity The buffering capacity of MOPS originates from the protonation deprotonation equilibrium between the sulfonic acid groups in its molecular structure and the morpholine ring. When the concentration of hydrogen ions in the solution changes, MOPS maintains pH stability by releasing or absorbing protons. Experiments have shown that the buffering capacity of MOPS is positively correlated with concentration within the range of 10-100 mM. For example, in protein ion exchange chromatography, a 10 mM MOPS buffer may result in a decrease in the separation between target proteins and impurity proteins due to insufficient buffer pairs; And 50 mM MOPS can achieve efficient separation of target proteins under specific elution conditions by precisely regulating the pH value of the mobile phase.But the higher the concentration, the better. When the concentration of MOPS exceeds 200 mM, the number of buffer pairs tends to saturate, and the effect of increasing concentration on pH stability significantly weakens. It may even interfere with the binding of proteins to chromatographic media due to high ion strength. In addition, high concentrations of MOPS may alter the fluidity of lipid membranes, affect the permeability of cell membranes, and thus interfere with the results of cell culture experiments. 2, Concentration sensitive window in cell culture Mammalian cells are extremely sensitive to the pH value of the culture medium, and MOPS, as a commonly used buffer component, should be strictly controlled at a concentration below 20 mM. Research has found that when the concentration of MOPS exceeds 20 mM, the thickness and barrier properties of the surface layer of rat endothelial cells change, resulting in a 15% -20% decrease in the efficiency of glucose uptake by cells. In addition, high concentrations of MOPS may interfere with the differentiation potential of embryonic stem cells by affecting calcium channel activity. 3, Practical points of concentration control Gradient testing method: For specific experimental systems, 5-10 MOPS concentration gradients (such as 5-100 mM) are pre designed, and the optimal concentration is determined by monitoring indicators such as pH stability, cell activity, or protein recovery rate. Compatibility verification: When using new chromatographic media or cell lines, it is necessary to verify the compatibility of MOPS concentration with the experimental system. For example, some metal chelation chromatography media may experience a decrease in performance due to the weak chelation of MOPS. Dynamic adjustment strategy: For long-term experiments (such as continuous cultivation or long-term electrophoresis), the effective concentration of MOPS can be maintained by adding buffer solution in stages to avoid pH loss due to buffer consumption. MOPS concentration control is a key link in the precision of life science experiments. By understanding the quantitative relationship between concentration, buffering capacity, and biological effects, and optimizing the buffering system based on specific experimental requirements, the reliability and reproducibility of experimental results can be significantly improved. In the future, with in-depth research on the interaction mechanism of MOPS molecules, concentration control strategies will become more refined, providing technical support for high-quality development in fields such as biopharmaceuticals and synthetic biology. Desheng is a professional manufacturer of biological buffering agents, established for more than ten years. It has rich experience in research and development, production, and product knowledge, and can provide customers with a large amount of technical support and after-sales guarantee. The biological buffer products currently produced include MOPS, TRIS, HEPES, TAPS, CAPS, BICINE, EPPS, PEP and a series of other biological buffer solutions. If you need them, please feel free to contact us at any time!